Summary by Moomoo AI
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The company, headquartered in Denmark, initiated this program on August 7, 2024, as part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024. From August 26 to August 30, 2024, Novo Nordisk repurchased a total of 204,000 B shares at an average price of DKK 910.88, amounting to a transaction value of DKK 185,845,531. This brings the accumulated repurchases under the program to 744,187 B shares for a total cost of DKK 671,844,599. As of August 30, the company owns 13,139,944 B shares as treasury shares, which is 0.3% of the share capital. The total number of A and B shares, including treasury shares, is 4,465,000,000. Since the beginning of the repurchase plan on February 6, 2024, Novo Nordisk has bought back 11,811,313 B shares at an average price of DKK 880.47 per share, totaling DKK 10,399,550,649. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
